3De Serres G, Gay NJ, Farrington CP. The epidemiology of transmissible diseases after elimination[J]. Am J Epidemiol, 2000, 151 (11) : 1039- 1048.
4Hinman AR, Orenstein WA, Papania MJ. Evolution of Measles Elimination Strategies in the United States[ J]. J Infect Dis, 2004,189 (Suppl 1 ) : S17-S22.
5de Quadros CA, Izurieta H, Venczel L, et al. Measles Eradication in the Americas: Progress to Date[J]. J Infect Dis, 2004, 189 ( Suppl 1 ) :S227-S235.
6Gay NJ. The Theory of Measles Elimination:Implications for the Design of Elimination Strategies[J]. J Infect Dis, 2004, 189 ( Suppl 1 ) : S27- S35.
7Aaby P, Determinants of measles mortality:host or transmission factors? [ A ]. de la Maza LM, Peterson EM, eds. Medical virology 10 : proceedings of the lOth International symposium on medical virology[ M]. 10th ed. New York : Plenum Press, 1991.83-116.
8WHO-UNICEF joint statement on strategies to reduce measles mortality worldwide[ J ]. Wkly Epidemiol Rec, 2002,77(27) : 224-228.
9Stittelaar K J, de Swart RL, Osterhaus AD. Vaccination against measles : a never ending story[J]. Expert Rev Vaccines,2002,1 (2) : 151-159.
10Hatziandreu EJ, Brown RE, Halpern MT. A cost-benefit analysis of the Measles-mumps- rubella (MMR) vaccine [ R ]. Arlington, VA : Battelle Medical Technology Assessment and Policy Research Program, 1994.1- 65.
